Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a single-centre, single-arm, phase 2 study to evaluate the efficacy and safety of
anlotinib hydrochloride plus everolimus in patients with advanced non clear renal cell
carcinoma as first-line treatment.